0LB2.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0LB2.L in your mock portfolio yet.
With EPS of 1.31 and a PE ratio of 38.50, the market is pricing in meaningful future growth relative to current earnings. The valuation looks rich for a company with modest recent price appreciation, suggesting expectations are high but not clearly supported by the limited fundamentals provided. Profitability exists, but without evidence of accelerating earnings or margin expansion, the risk of multiple compression remains.
The stock at $50.59 is trading well above its 200-day moving average of $29.84, indicating a strong longer-term uptrend that has already played out. However, the RSI at 35.47 is close to oversold territory, suggesting near-term selling pressure or consolidation after a strong run. The modest 0.7% gain over the last month points to a pause rather than a clear new leg higher or breakdown.
Web traffic of 18,722 visitors per month appears modest for a commercial-stage pharma, and there is no evidence of strong digital demand growth in the data provided. Social media signals are weak: Twitter/X followers are small and declining, and LinkedIn followers are flat, indicating limited momentum in brand visibility or hiring-driven expansion. Overall, alternative data do not currently support a strong growth narrative.
Supernus Pharmaceuticals shows a profitable business with a stock price that has already moved strongly higher over the longer term and now trades at a premium valuation. Technicals point to consolidation after a major uptrend, while alternative data are soft and do not reinforce a strong growth or engagement story. Taken together, the setup appears balanced: upside depends on future execution and pipeline/earnings delivery, while downside risk stems from a high multiple and weak alternative signals.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: